Guidelines
Moderate COVID

Moderate COVID

Treatment

Dexamethasone: 0.15mg/kg/dose PO or IV (Max 6 mg/dose) once daily for up to 10 days or until discharge from hospital, if sooner.

Remdesivir:

For children ≥40 Kg: 200 mg IV q24h x1, then 100mg IV q24h x 4 days

For children <40 Kg: 5mg/kg/dose IV x1, then 2.5 mg/kg/dose IV q24h x 4 d 

For infants <3.5 Kg: 2.5mg/kg/dose IV x1, then 1.25mg/kg/dose IV q24h x 4 d

  • Risk factors for progression to severe disease include, but are not limited to:
    • obesity
    • neurological comorbidities
    • chronic respiratory disorders
       
  • Populations that may be at higher risk for severe infection include infants <1 year of age and children with comorbid conditions including:
    • lung disease
    • immune compromise
    • obesity
    • congenital heart disease
    • sickle cell disease
    • genetic abnormalities
    • neurological disease
    • diabetes mellitus

CMAJ 2021 Sept 27;193

  • Other potential causes of pneumonia, such as non-SARS-COV-2 respiratory viruses, Streptococcus pneumoniae, Staphylococcus aureus and other bacterial pathogens should be considered in all children admitted with suspected COVID-19.
  • Common organisms implicated in secondary bacterial pneumonia for influenza include; Streptococcus pneumoniae, Staphylococcus aureus, and non-typable Haemophilus influenzae.

Remdesivir Considerations